Back to top

CytoDyn Inc. (CYDY)

(Delayed Data from OTC)

$2.69 USD


-0.10 (-3.71%)

Updated May 6, 2021 03:59 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
5Strong Sell3.06%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (206 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.

General Information

CytoDyn Inc.



Phone: 360-980-8524

Fax: NA



Industry Medical - Drugs
Sector Medical
Fiscal Year End May
Last Reported Quarter 2/28/2021
Next EPS Date 8/13/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.05
Current Year EPS Consensus Estimate -0.21
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 8/13/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 2.79
52 Week High 10.01
52 Week Low 1.63
Beta -0.59
20 Day Moving Average 2,688,382.50
Target Price Consensus 0.00


% Price Change
4 Week -20.19
12 Week -49.58
YTD -48.17
% Price Change Relative to S&P 500
4 Week -21.86
12 Week -52.69
YTD -53.29
Share Information
Shares Outstanding (millions) 619.04
Market Capitalization (millions) 1,729.28
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -20.00%
vs. Previous Quarter 0.00%
Sales Growth
vs. Previous Year NA%
vs. Previous Quarter NA%
Price Ratios
Price/Book NA
Price/Cash Flow NA
Price / Sales NA
2/28/21 NA
11/30/20 NA
8/31/20 NA
2/28/21 -134.05
11/30/20 -153.30
8/31/20 -207.71
Current Ratio
2/28/21 0.86
11/30/20 1.13
8/31/20 1.05
Quick Ratio
2/28/21 0.13
11/30/20 0.27
8/31/20 0.28
Operating Margin
2/28/21 NA
11/30/20 NA
8/31/20 NA
Net Margin
2/28/21 NA
11/30/20 NA
8/31/20 NA
Pre-Tax Margin
2/28/21 NA
11/30/20 NA
8/31/20 NA
Book Value
2/28/21 -0.03
11/30/20 -0.01
8/31/20 0.00
Inventory Turnover
2/28/21 0.00
11/30/20 0.00
8/31/20 0.00
2/28/21 NA
11/30/20 NA
8/31/20 5.01
Debt to Capital
2/28/21 NA
11/30/20 NA
8/31/20 83.35